CXO Talks: Cary Claiborne from Adial Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Welcome to the sixth episode of CXO Talks, featuring Cary Claiborne, CEO of Adial Pharmaceuticals a clinical-stage biopharmaceutical company dedicated to developing therapies for the treatment and prevention of addiction and related disorders.

Taking a walk down memory lane, Cary shares the inspiration behind founding Adial Pharmaceuticals. He recounts how an early study at the University of Virginia, which identified the effectiveness of a serotonin-3 blocker against specific genetic markers, laid the foundation for the company’s origin story.

Cary also elaborated on Adial’s lead candidate, AD04, for which the company recently announced a database lock in its PK study. Topline results are anticipated by the end of the fourth quarter.

About the Author:

Cary Claiborne

As CEO of Adial Pharmaceuticals, a NASDAQ-listed company pioneering innovative treatments for addiction, Cary leads the organization’s strategic vision, operational execution, and financial performance. With over 35 years of diverse multinational business experience, he brings extensive expertise in the pharma and biotech sectors, complemented by a proven track record of delivering results.

Beyond his role at Adial, Cary serves as a board member and committee chair for two other public biotech companies NeuroSense Therapeutics (Nasdaq: NRSN) and LadRx Corporation (LADX) contributing to their governance, oversight, and growth. He was previously recognized as a NACD Corporate Director Fellow, reflecting his commitment to excellence in board leadership and corporate governance.

Cary’s accolades include nominations for prestigious awards, such as CFO of the Year by the Tech Council of Maryland and the Northern Virginia Technology Council. His mission is to leverage his analytical skills, strategic vision, and M&A expertise to create value for shareholders, stakeholders, and society.